STUDY DESIGN:
Randomised controlled, blinded clinical trial.
SUBJECTS:
The study will include 120 patients with definite diagnosis of MCI or AD and 30 young healthy subjects and 30 old healthy subjects referred to the Research Unit associated with the Department.
Patients will be regarded as suitable to participate if they fulfilled the following criteria:
* Mini Mental State Examination (MMSE) ≥ 8;
* Performance Oriented Mobility Assessment ≥ 19 (POMA).
Exclusion criteria will be:
* presence of other concurrent neurological diseases;
* presence of other orthopaedic diseases involving the lower limbs and/or interfering with standing position and/or walking;
* presence of severe auditory and visual deficits not corrected;
* abuse of alcohol or drugs;
* psychiatric disorders,
* severe behavioral disorders;
* hearth and respiratory disease that interfere with the motor activity. The protocol was be approved by the local ethics committee with number 2389. All participants will perform a physiatric examination by a medical doctor of the Department of Neurological and Movement Sciences. Written inform consent will be obtained from all participants before inclusion in the study.
Participants who will meet the inclusion criteria will conduct a clinical and instrumental evaluation at enrollment (T0) and after 6 months ± 15 days after the first visit (T1). The assessment procedures will also be repeated after 3 months (T2) from T1.
ASSESSMENT PROCEDURES
Primary endpoints:
\- score obtained in the Mini Mental State Examination.
Secondary endpoints:
\- score obtained in a cognitive battery.
For MCI patients will be used:
* Trial Making Test (Reitan,1958),
* Rivermead Behavioral Memory Test (Wilson, 1989),
* Tower of London (Shallice, 1982),
* Dual Task (Della Sala et al., 1997),
* Frontal Assessment Battery (Iavarone A et al., 2004).
For AD patients will be used:
* Attention Matrix (Spinnler et al., 1987),
* Alzheimer's Disease Assessment Scale (Rosen WG et al., 1984),
* Frontal Assessment Battery (Iavarone A et al., 2004).
\- score obtained in a motor skills assessment composed by:
* 6-Minute Walking Test (Ries JD et al., 2009),
* gait analysis by GAITRite® System (Bilney B et al., 2003),
* stabilometric assessments with Stability Line (Nashner LM and Peters JF, 1990),
* score obtained in the test Instrumental Activity in Daily Living (Lawton MP and Brody EM, 1969),
* score obtained in the test Neuropsychiatric Inventory (Cummings JL et al., 1994),
* peripheral vascular function measured by doppler.
To evaluate the effectiveness of motor treatment, compared to a cognitive treatment on motor skills, cognitive skills, behavioral and autonomy in patients with cognitive decline, all patients will be evaluated by motor, cognitive, behavioral and autonomy scales, at baseline, after 6 months (T1), and after others 3 months (T2). A subgroup of 50% of patients will undergo instrumental procedures to investigate the effects of treatments on cerebral blood flow (arterial spin labeling).
TREATMENT PROCEDURES
The participants will be recruited and randomly assigned, according to the degree of cognitive decline, to one of the 3 groups (7-8 subjects):
* Physical Activity group (PA group): It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
* Cognitive treatment group (CT group): The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems The PA and CT groups will be homogeneous for clinical and demographic data, and participants will undergo 72 treatment group sessions, 60-minute/session, and 3 days/week for 6 consecutively months.
Both types of treatment will be balanced with different degrees of difficulty depending on the state of disease severity .
o The control groups (CG) will not receive any such treatment during the study and they will be evaluated by the same clinical and instrumental assessments.
